pharmaceut rate downgrad unit state go sg websit
long-term challeng still mispric downgrad hold buy
nc chang
hold buy
upsid tp
oppos forc ye near-term growth low risk well ahead
sector averag thank cost save financi de-lever relat
celgen deal stock may also deem good valu short-term
multipl could benefit near-term catalyst phase data
skin drug despit manag updat next week
struggl envisag pro forma pipelin provid option
requir sustain top-lin growth decad henc over-rid
concern manag anoth larg deal soon
group return net cash posit balanc choos
wait see cut rate hold buy tp
chang cut core ep forecast care
assess new pro forma inform releas stage realis
underestim bmss pro-forma oper cost although bare chang sale
forecast ahead consensu expect translat bottom-
line upgrad view market underestim organ
invest manag need make tri transform bmss bleak long-term
growth prospect forecast lower ep place stock
bottom peer group metric consider distanc
calcul target price still use simpl averag three-year forward
ev/ebita multipl dcf automat consid stock short-
long-term growth prospect cut tp due lower
estim new tp impli mid-forti percentag discount global peer
ep think strike right balanc stock premium near-term growth
prospect long-term challeng input dp estim project tsr
coupl deterior fundament put stock sg hold band
could wrong els equal three largest upsid risk pro
forma ebita forecast bmss promis late-stag organ pipelin drug
psoriasi inflamm skin ramp twice quickli market
leader gener competit revlimid celgen largest legaci drug myeloma
common form blood cancer meet consensu gener competit
celgen pomalyst also myeloma prove benign consensu expect
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
squibb corpor found brooklyn new york edward robinson
john ripley myer william mclaren bristol acquir clinton
decid renam bristol myer compani two
compani merg creat bristol myer squibb bm bm acquir
medarex part string pearl strategi allianc partnership acquisit
medarex key asset immunotherapi io drug opdivo bmss import
growth driver see tabl dr giovanni caforio chairman ceo sinc
januari compani announc intent acquir us biotech compani
celgen n/r cash stock deal approv set sharehold
april offici complet novemb
product relev invest debat
develop medarex ono
us book sale co-market us
us volum limit gener competit
enter celgen pipelin via acquisit recepto
reason
robust averag near-term growth
reason
sg forecast pro forma sale ep contract everi year
progress dividend polici intact post equiti issuanc celgen
chang
initi coverag bm sell rate april link time thought
consensu estim discount optimist scenario compani prospect
cancer immunotherapi io thesi back specif predict high-profil
checkmat phase trial would fail august year howev strong
convict market optimist extrapol compani initi io
domin melanoma mani type cancer upgrad stock buy
januari believ celgen acquisit sensibl first step
attempt transform compani bleak long-term fundament chart left
howev cut ep forecast tabl previous
underestim bmss start pro forma oper cost sale estim essenti
unchang new mid-term ep forecast consensu tabl
believ market underestim invest manag need
make develop pipelin materi enough drive sustain growth long
pro forma non-gaap-ep chang sg estim comparison consensu
downgrad ep estim reflect view bm continu face greater
challeng peer reinvent long term see chart left posit
correspond free cash analysi expect manag execut well
integr celgen acquisit forecast net cash posit
combin entiti non- basi see chart right
henc believ bm ampl financi flexibl engag materi
 prior eliqui patent expiri organ pipelin unabl creat
non gaap ep percentag
note includ risk-adjust cash outflow celgen conting valu right
cvr
valu stock
us enjoy spectacular rerat first half last decad excit
surround potenti cancer immunotherapi io pipelin increas see chart
left howev sinc share suffer sever multipl contract compani
execut poorli io moreov subsequ announc celgen
acquisit januari initi drove anoth derat stock market
seem believ deal would lead deterior uss long-term
fundament view explain stock outlier vs global peer group chart
right
continu base pharma stock target price unweight averag three-year
forward ev/ebita multipl dcf automat take account stock short-
long-term growth prospect tp decreas
downgrad describ
premium/discount sector
still assum wacc perpetu growth rate
new tp impli pro forma price-to-earnings discount global pharma univers
tabl due scale challeng manag face tri transform
compani long-term growth prospect see chart right
could wrong
revlimid gold standard first-lin treatment multipl myeloma one
common type blood cancer moreov drug account celgen
total stand-alone revenu estim even higher proport group profit
view drug reput essenti sell cheap produc
us celgen expect revlimid face volume-limit gener competit us
march due term latter legal settlement gener manufactur
natco alvogen settlement allow launch volume-limit gener sometim march
us celg us expect aggress multi-sourc gener
competit drug us commenc januari celgen agreement
accord also allow latter launch gener europ see slide
revlimid estim consensu tabl wrong
drug achiev market forecast year assum contribut margin
would mid-single-digit percentag upsid group ebita
revlimid chang sg estim comparison consensu
pomalyst pomalidomid deriv thalidomid ccc fda first approv drug
treatment relaps refractori multipl myeloma product current
indic use combin dexamethason patient receiv least
two prior therapi includ revlimid proteasom inhibitor velcad ninlaro
manufactur takeda
pomalyst chang sg estim comparison consensu
upgrad near-term pomalyst forecast tabl follow better-than-
expect result report januari howev eu patent drug
expir us patent expect latter event impact sale
neg former us gener market effici
understand celgen file patent infring action gener
compani file applic sell gener version pomalyst drug
annual report indic trial schedul litig juli august
suspect pomalyst estim consensu tabl
market comment expect celgen sign out-of-court settlement
challeng drug intellectu properti henc wrong drug achiev
market forecast year assum contribut margin would
mid-single-digit percentag upsid group ebita
recap celgen launch otezla inhibitor treatment psoriasi
drug achiev revenu growth howev bm decid sell
product facilit consumm celgen
acquisit competit author express concern potenti overlap otezla
see would mean combin compani would exercis
much control market tablet-bas psoriasi drug
tyrosin new class tablet-bas drug develop address
auto-immun diseas psoriasi potenti better toler exist
oral therapi like otezla xeljanz consensu sale view
highest profil pipelin drug bristol myer squibb organ late-stag pipelin bms-
current phase trial psoriasi see quot accord
comprehens us pharma clinic trial databas www clinicaltri gov result
studi due report see tabl understand bmss ir
studi power show superior activ compar otezla
select allow target specif cytokin pathway
type interferon implic
psoriasi absenc neutropenia elev liver enzym level serum
creatinin level dyslipidemia advers effect observ clinic
trial jak inhibitor target similar cytokin consist differ
activ two class drug phase data peer review new england
journal medicin octob
moder sever plaqu
moder sever plaqu
phase moder sever plaqu
ultra high risk
ultra high risk
ultra high risk
ultra high risk
opinion leader kol psoriasi met much enthusiast
potenti otezla jak inhibitor
view former less like caus side effect howev err side caution
assum similar sale trajectori otezla see chart howev
wrong ramp twice quickli otezla achiev
 year chart sale contribut margin would
high-single-digit upsid group ebita
bm part jone north american index lead sustain compani
summaris compani address environment social govern
esg aspect busi
view appropri manag system compani
environ health safeti group monitor global oper help implement
complianc standard thu meet regulatori requir sinc compani
reduc water consumpt vs reduct target scope scope
green-hous ga emiss vs reduct target absolut energi
consumpt bm reduc hazard wast product
total wast gener increas period
board structur giovanni caforio ceo chairman board director bristol
myer squibb member group board director elect annual current
total women
capit structur end compani outstand common stock
carri one vote right compani also convert
prefer stock liquid prefer convert prefer stock vote
singl class along bristol-my squibb common stock share entitl
holder singl vote
access medicin bm sever company-wid polici programm provid
access drug particularli low- middle-incom countri compani csr arm
bm foundat work improv outcom popul affect hiv/aid
hepat type diabet cancer foundat also work improv
mental health militari veteran
us bm donat medicin under-
developed/develop countri fight number diseas also grant immun
lawsuit certain manufactur poor countri manufactur cheap gener version
hiv drug
capit manag bm employe take respons
employe health safeti divers inclus overal well-b serious
bm achiev score year row corpor equal index
cei lgbtq equal also top-scor compani disabl equal index
forecast product sale financi statement
product sold
net earn attribut
total liabil equiti
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
chang wc
share
tabl model impact central scenario posit
neg take relev product current portfolio late-stag
pipelin help us calibr magnitud risk compani face go
forward use ebit analysi given long product cycl
pharmaceut industri forecast downsid risk
ebit upsid risk vs
sale varianc sourc upsid downsid
ebit varianc sourc upsid downsid
driver drag sale
 revenuedeclin revenu sale
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
straight averag sotp still valu pariti sector ev/ebita multipl dcf still assum wacc
termin growth lower
three largest upsid risk pro forma ebita forecast would bmss promis organ pipelin drug ramp
twice quickli market leader gener competit revlimid celgen largest legaci drug myeloma common
form blood cancer achiev consensu forecast gener competit pomalyst also myeloma benign
downsid risk manag could engag anoth major acquisit back net cash
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
report contain contribut research team esg numer rate highest score base
four step rate methodolog includ identifi materi esg factor associ weight sector ii provid key
perform indic compani evalu iii calcul quantit esg rate base sustainalyt data combin sg equiti
esg rate identifi top pick esg rate group three equal tier tier tier contain compani
highest esg numer score esg numer rate consid fundament rate kind complet
separ sg equiti credit rate
sg partner sustainalyt independ provid esg data research support servic gather esg data use
public sustainalyt affili sg sg warrant complet accuraci sustainalyt analysi data
